I was a BOD holder as well.
BOD was probably history without this deal.
Sure the dilution hurt , but better than ending up with nothing
they had no money to continue the development, so would have been diluted or sold off the IP
Then once they had developed Cardiocel, they wouldn't have had a clue how to market and sell it. They never sold anything they tried to develop.
BOD board had a potentially good product , couldn't fund it, and didn't have a clue what to do with it if developed.
They took the smart option and handed over the reigns.
If they didn't, you are probably looking at best, BOD still having a product with potential, no money, no revenue and no immunotherapy division.
I prefer being part of AHZ.
AHZ Price at posting:
6.6¢ Sentiment: Hold Disclosure: Held
